Conduit Pharmaceuticals (CDT) said Thursday it partnered with Charles River Laboratories International (CRL) to evaluate its AZD1656 drug candidate and its derivatives in a preclinical model of systemic lupus erythematosus, as part of its strategy to develop potential immunotherapies for autoimmune disorders.
Financial terms of the collaboration were not disclosed, but Conduit said that Charles River will assist in refining study parameters and generating robust preclinical data to optimize the development pathway for AZD1656 ahead of its planned Phase 2 clinical trials.
The primary goal is to better understand how AZD1656 affects disease progression in a lupus model compared with typical disease outcomes, according to the company.
The study will also assess the impact of AZD1656 on inflammatory markers and pro-inflammatory cytokine levels to evaluate its potential for Treg immunoregulation, which could inform and de-risk future clinical trials.
Conduit shares recently were sliding nearly 5% lower while Charles River was down 0.3% in Thursday morning trade.
Price: 1.70, Change: -0.09, Percent Change: -4.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。